A Phase I Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2009
At a glance
- Drugs AS 1409 (Primary)
- Indications Malignant melanoma; Renal cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 26 Aug 2009 Actual patient number (13) added as reported by ClinicalTrials.gov.
- 26 Aug 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.